- Home
- APRE
as 11-24-2025 10:09am EST
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DOYLESTOWN |
| Market Cap: | 6.9M | IPO Year: | 2019 |
| Target Price: | $20.00 | AVG Volume (30 days): | 84.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.08 - $5.00 | Next Earning Date: | 11-12-2025 |
| Revenue: | $488,239 | Revenue Growth: | -62.75% |
| Revenue Growth (this year): | -80.92% | Revenue Growth (next year): | N/A |
Latest Aprea Therapeutics Inc. Common stock News
APRE Breaking Stock News: Dive into APRE Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update
GlobeNewswire
a month ago
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
GlobeNewswire
a month ago
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
GlobeNewswire
a month ago
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire
3 months ago
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
MT Newswires
5 months ago
Aprea Says APR-1051 Shows Early Disease Control in HPV-Positive Head and Neck Cancer
Simply Wall St.
5 months ago
Pleasing Signs As A Number Of Insiders Buy Aprea Therapeutics Stock
GlobeNewswire
5 months ago
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
Compare APRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APRE Aprea Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.